The company has permission for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO).
Lilly signs pacts with Cipla, Lupin, Sun Pharma to accelerate availability of baricitinib for Covid-19 patients ANI | Updated: May 10, 2021 12:25 IST
Lily is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses. These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India, it said in a statement.
Lilly recently received permission for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health for baricitinib to be used in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-
Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in India
yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
Eli Lilly signs deals to boost supply of COVID-19 treatment in India
05/10/2021 | 04:01am EDT
Send by mail :
Message :
Required fields
BENGALURU (Reuters) -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
The agreements will bolster India s arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.
The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.
Eli Lilly signs agreements with Cipla, Lupin and Sun Pharma
By IANS |
Published on
Mon, May 10 2021 12:06 IST |
6 Views
Mumbai Port Trust to sign MoUs of worth Rs 1,860 cr at Maritime Summit. Image Source: IANS News
New Delhi, May 10 : Eli Lilly announced that it has issued royalty-free, non-exclusive voluntary licenses to Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd., Lupin Ltd. and Sun Pharmaceutical Industries Ltd., who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India.
Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.
These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling Eli Lilly signs agreements with Cipla, Lupin an